Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1KAVV | ISIN: IE00B91XRN20 | Ticker-Symbol: 0PT
Tradegate
12.02.26 | 15:09
7,500 Euro
-0,66 % -0,050
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
PROTHENA CORPORATION PLC Chart 1 Jahr
5-Tage-Chart
PROTHENA CORPORATION PLC 5-Tage-Chart
RealtimeGeldBriefZeit
7,3507,55012.02.
7,4507,50012.02.

Aktuelle News zur PROTHENA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoProthena Corporation plc: Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026165Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
12.12.25Prothena Announces Board of Directors Update2
12.12.25Paula Cobb steps down from Prothena's board to join Manifold Bio2
12.12.25Prothena Corporation plc: Prothena Announces Board of Directors Update373Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
12.12.25PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report1
01.12.25Prothena: Citizens hebt Kursziel deutlich auf 19 US-Dollar an19
01.12.25Prothena stock price target raised to $19 from $11 at Citizens2
19.11.25Prothena presents TDP-43 CYTOPE data showing promise for ALS treatment2
PROTHENA Aktie jetzt für 0€ handeln
19.11.25Prothena Corporation plc: Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025316TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena's CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular...
► Artikel lesen
19.11.25PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report-
11.11.25Prothena Corporation plc: Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA553Novo Nordisk's Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo Nordisk...
► Artikel lesen
10.11.25H.C. Wainwright raises Prothena stock price target to $30 on partnered pipeline value2
06.11.25Prothena Reports Third Quarter 2025 Financial Results and Business Highlights1
06.11.25Prothena Corporation plc: Prothena Reports Third Quarter 2025 Financial Results and Business Highlights634Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash...
► Artikel lesen
06.11.25Prothena GAAP EPS of -$0.68 beats by $0.01, revenue of $2.4M misses by $4.24M5
30.10.25Prothena Corporation plc: Prothena to Report Third Quarter 2025 Financial Results on November 6290Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
28.10.25Prothena stock price target raised to $36 from $15 at Piper Sandler8
08.10.25Prothena stock price target raised to $20 from $14 at H.C. Wainwright2
07.10.25Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)3
01.10.25Prothena Corporation plc: Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease479Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential...
► Artikel lesen
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1